Plasma cell myeloma
Therapeutic area
Immunology
Rare disease
Yes
- Definition
- A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Plasma cell myeloma
- Therapeutic area
- Immunology
- plasma cell myeloma
- Kahler disease
- Kahler's disease
- Multiple Myeloma
- medullary plasmacytoma
- multiple myeloma
- multiple myeloma, resistance to, Somatic mutation
- multiple myeloma, susceptibility to, Somatic mutation
- multiple myeloma/plasma cell myeloma
- myeloid neoplasm of plasma cell
- myeloma
- myeloma, multiple
- myeloma, plasma cell, malignant
- myelomatosis
- plasma cell myeloid neoplasm
- plasma cell myeloma
- myeloma - multiple
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0009693
- Parent condition
- MONDO:0000621
Related records
Broader conditions (21)
- B-cell neoplasm
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system cancer
- Immune system disorder
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Myeloid neoplasm
- Neoplasm
- Neoplasm of mature B-cells
- Neoplastic disease or syndrome
Narrower conditions (4)
- Indolent plasma cell myeloma
- Non-secretory plasma cell myeloma
- Osteosclerotic plasma cell myeloma
- Smoldering plasma cell myeloma
Trials (3,795)
- "FU-IFM2009" Database Post IFM/DFCI 2009 Study
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- "Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma
- "WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival
- 1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- 18F-Fluciclovine PET/CT in Multiple Myeloma
- 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
- 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients
Approved drugs (29)
- Belantamab mafodotin
- Bortezomib D-mannitol
- Carfilzomib
- Carmustine
- Ciltacabtagene autoleucel
- Cyclophosphamide
- Daratumumab
- Dexamethasone acetate
- Doxorubicin hydrochloride
- Elotuzumab
- Elranatamab
- Idecabtagene vicleucel
- Interferon alfa-2B
- Isatuximab
- Ixazomib citrate
- Lenalidomide
- Lenalidomide hydrochloride monohydrate
- Melphalan
- Melphalan flufenamide hydrochloride
- Melphalan hydrochloride
Drugs in development (451)
- (R)-melphalan Phase 3
- 2-methoxyestradiol Phase 2
- 6-O-benzylguanine Phase 2
- A27.15 Phase 1
- Abatacept Phase 2
- ABBV-467 Phase 1
- ABC-294640 Phase 1
- Abemaciclib Phase 1
- Acalabrutinib Phase 1
- Acetaminophen Phase 3
- Actinium AC 225 dotatate Phase 1
- Adavosertib Phase 2
- AEW-541 Phase 1
- Afatinib Phase 2
- Afatinib dimaleate Phase 2
- Aflibercept Phase 2
- Afuresertib Phase 1
- Aldesleukin Phase 2
- Alemtuzumab Phase 1
- Alethine Phase 1
Other linked drugs (8)
- Bortezomib
- Cerivastatin
- Dacinostat
- Futibatinib
- Lisocabtagene maraleucel
- Tagraxofusp
- Trapidil
- Zoxazolamine